<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04860804</url>
  </required_header>
  <id_info>
    <org_study_id>2021-02-02-MMC</org_study_id>
    <nct_id>NCT04860804</nct_id>
  </id_info>
  <brief_title>A Comparison of Proprietary Formulations of Oral Ketamine + Aspirin and Oral Ketamine Alone for Musculoskeletal Pain</brief_title>
  <official_title>A Comparison of Proprietary Formulations of Oral Ketamine + Aspirin and Oral Ketamine Alone in Adult Patients Presenting to the ED With Acute Musculoskeletal Pain: Prospective, Randomized, Open-Label, Clinical Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Antonios Likourezos</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Maimonides Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Acute Pain is one of the most frequent chief complaints and the main reason for visiting the&#xD;
      Emergency Department (ED). The acute pain in the ED is largely prevalent across the country&#xD;
      with recent literature demonstrating that 61-91% of patients are admitted to the ED due to a&#xD;
      variety of acute painful syndromes. There is a lack of good options for pain control in such&#xD;
      settings.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      STUDY OBJECTIVES: To compare analgesic efficacy and rates of side effects of a proprietary&#xD;
      formulation of orally administered aspirin and ketamine (AOK) to a proprietary formulation of&#xD;
      Oral Ketamine (OK) (VTS-K formulations) for pain management in adult ED patients presenting&#xD;
      to the ED with acute musculoskeletal pain HYPOTHESIS: The investigators hypothesize that the&#xD;
      administration of AOK will provide better analgesia at 60 minutes post-administration in&#xD;
      comparison to OK in adult patients presenting to the ED with acute musculoskeletal pain. The&#xD;
      primary outcome of this trial is the comparative reduction in participant's pain scores at 60&#xD;
      minutes post-medication administration.&#xD;
&#xD;
      STUDY DESIGN:&#xD;
&#xD;
      Subjects: Patients 18 years of age and older presenting to the ED with acute musculoskeletal&#xD;
      painful conditions (traumatic and non-traumatic) with an initial pain score of 5 or more on a&#xD;
      standard 11-point (0 to 10) numeric rating scale and requiring oral analgesia as determined&#xD;
      by the treating attending physician. Patients' screening and enrollment will be performed by&#xD;
      study investigators and research assistants. All patients will be enrolled at various times&#xD;
      of the day when study investigators will be available for patient enrollment and an ED&#xD;
      pharmacist will be available for medication preparation.&#xD;
&#xD;
      Design: This is a prospective, randomized, open-label trial comparing analgesic efficacy and&#xD;
      safety of AOK and OK in patients presenting to the ED of Maimonides Medical Center with acute&#xD;
      musculoskeletal pain. Upon meeting the eligibility criteria, patients will be randomized into&#xD;
      one of the two study arms: Group I will receive AOK and Group II will receive OK.&#xD;
&#xD;
      Data Collection Procedures: Each patient will be approached by a study investigator for&#xD;
      acquisition of written informed consent and Health Insurance Portability and Accountability&#xD;
      Act authorization after being evaluated by the treating emergency physician and determined to&#xD;
      meet study eligibility criteria. When English will not be the participant's primary language,&#xD;
      a language- appropriate consent form will be used and non-investigator, hospital employed,&#xD;
      trained interpreters or licensed telephone interpreters will assist in acquisition of&#xD;
      informed consent. Baseline pain score will be determined with an 11-point numeric rating&#xD;
      scale (0 to 10), described to the patient as &quot;no pain&quot; being 0 and &quot;the worst pain&#xD;
      imaginable&quot; being 10. A study investigator will record the patient's body weight and baseline&#xD;
      vital signs. All data will be recorded on data collection sheets, including patients' sex,&#xD;
      demographics, medical history, and vital signs, and entered into SPSS (version 24.0; IBM&#xD;
      Corp) by the research manager. Confirmation of written consent acquisition for all&#xD;
      participants, and statistical analyses will be conducted by the statistician, who will work&#xD;
      independently of any data collection.&#xD;
&#xD;
      Expected Outcomes: The primary outcome will include a reduction from baseline of pain scores&#xD;
      on numeric rating pain scale (NRS) at 60 minutes. The secondary outcomes will include a need&#xD;
      for rescue analgesia and rates of adverse up to 120 minutes. With respect to unique adverse&#xD;
      effects of SDK, we will use Side Effect Rating Scale for Dissociative Anesthetics (SERSDA)&#xD;
      and Richmond Agitation Sedation Scale (RASS). SERSDA Scale includes fatigue, dizziness,&#xD;
      nausea, headache, feeling of unreality, changes in hearing, mood change, general discomfort,&#xD;
      and hallucinations with severity of each graded by patients on a five-point scale, with &quot;0&quot;&#xD;
      representing the absence of any adverse effects and &quot;4&quot; representing a severely bothersome&#xD;
      side effect. RASS evaluates the severity of agitation and/or sedation in accordance to the&#xD;
      nine-point scale with scores ranging from &quot;-4&quot; (deeply sedated) to &quot;0&quot; (alert and calm) to&#xD;
      &quot;+4&quot; (combative).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 22, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction in Pain score at 60 minutes</measure>
    <time_frame>60 minutes</time_frame>
    <description>Reduction of pain scores on numeric rating pain scale (NRS) at 60 minutes mark form the baseline. The NRS is an 11 item Likert Scale ranging from 0 (no pain) to 10 (very severe pain) with 5 indicating moderate pain.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>AOK Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Drug: Proprietary oral formulation of 0.5mg/kg of ketamine + 324mg of aspirin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OK Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Drug: Proprietary oral formulation of 0.5mg/kg of ketamine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin and Ketamine</intervention_name>
    <description>Drug: Proprietary oral formulation of 0.5mg/kg of ketamine + 324mg of aspirin</description>
    <arm_group_label>AOK Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral Ketamine</intervention_name>
    <description>Proprietary oral formulation of 0.5mg/kg of ketamine</description>
    <arm_group_label>OK Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients age 18 and older&#xD;
&#xD;
          -  acute musculoskeletal pain&#xD;
&#xD;
          -  initial pain score of 5 or more on a standard 11- point (0 to 10) numeric rating&#xD;
             scale.&#xD;
&#xD;
          -  awake, alert, and oriented to person, place, and time&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  altered mental status,&#xD;
&#xD;
          -  allergy to aspirin and ketamine,&#xD;
&#xD;
          -  pregnant&#xD;
&#xD;
          -  unstable vital signs (systolic blood pressure &lt;90 or&gt;180 mm Hg, pulse rate &lt;50 or &gt;150&#xD;
             beats/ min, and respiration rate &lt;10 or &gt;30 breaths/min)&#xD;
&#xD;
          -  inability to provide consent&#xD;
&#xD;
          -  consumption of Aspirin or NSAID's within 6 hours of arrival to the ED&#xD;
&#xD;
          -  active PUD&#xD;
&#xD;
          -  history of GI Hemorrhage&#xD;
&#xD;
          -  history of renal and hepatic insufficiency&#xD;
&#xD;
          -  past medical history of alcohol or drug abuse&#xD;
&#xD;
          -  schizophrenia&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Leily Naraghi Bagher Pour, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maimonides Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Antonios Likourezos, MA, MPH</last_name>
    <phone>7182836896</phone>
    <email>alikourezos@maimonidesmed.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Leily Naraghi Bagher Pour, MD</last_name>
    <email>LNaraghi@maimonidesmed.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Maimonides Medical Center</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonios Likourezos, MA, MPH</last_name>
      <email>alikourezos@maimonidesmed.org</email>
    </contact>
    <contact_backup>
      <last_name>Leily Naraghi Bagher Pour, MD</last_name>
      <email>LNaraghi@maimonidesmed.org</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 22, 2021</study_first_submitted>
  <study_first_submitted_qc>April 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 27, 2021</study_first_posted>
  <last_update_submitted>October 12, 2021</last_update_submitted>
  <last_update_submitted_qc>October 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Maimonides Medical Center</investigator_affiliation>
    <investigator_full_name>Antonios Likourezos</investigator_full_name>
    <investigator_title>Research Administration Director</investigator_title>
  </responsible_party>
  <keyword>Emergency Medicine, Pain, Pain Management, Musculoskeletal</keyword>
  <keyword>Emergency Medicine</keyword>
  <keyword>Pain</keyword>
  <keyword>Pain Management</keyword>
  <keyword>Musculoskeletal</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Musculoskeletal Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Ketamine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 23, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/04/NCT04860804/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

